Amgen Assist 360™ is a single place for patients, caregivers, and healthcare professionals to go to find the support, tools, and resources most important to them.
Amgen SupportPlus is a single place for patients, caregivers, and healthcare professionals to go to find the support, tools, and resources most important to them.
Submit, store, and retrieve benefit verifications for all patients currently on Amgen medications electronically with ease from our secure Amgen SupportPlus Provider Portal.
AMGEN SUPPORTPLUS REPRESENTATIVES
Call an Amgen SupportPlus Representatives directly for your benefit verification needs.
AMGEN ACCESS SPECIALISTS
Schedule a remote or live appointment with a Amgen Access Specialist who can assist with:
AMGEN® NURSE PARTNERS* ARE AVAILABLE TO SUPPORT YOUR PATIENTS
Dedicated Amgen Nurse Partners can offer supplemental support and provide information about resources to help patients access their prescribed medication.
Patients can learn about independent nonprofit organizations† that may provide community resources, one-on-one counseling services, and local support groups.
| Co-Pay Program
Helping eligible patients save on
The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.
Encourage your patients with private or commercial insurance to check eligibility and
enroll at www.AmgenSupportPlus.com/copay
‡ Terms, conditions, and program maximums apply. Other restrictions may apply. See www.AmgenSupportPlus.com/copay for full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
AMGEN HAS AN UNWAVERING COMMITMENT TO DELIVER OUR PRODUCTS, INCLUDING MVASI®, TO EVERY PATIENT, EVERY TIME
Resource Guide contains billing and coding information, supply, preparation and dosing information plus support services.
*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.
Order resources to help you administer MVASI® and guide conversations with patients. Or, learn more about prescribing MVASI® for your patients.
Important Safety Information
Serious adverse reactions (Warnings and Precautions)
Most common adverse reactions
Indication-specific adverse reactions
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Amgen at 1-800-772-6436.
Please see full Prescribing Information for additional Important Safety Information.
MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of:
MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC).
MVASI®, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen.
Limitations of Use: MVASI® is not indicated for adjuvant treatment of colon cancer.
MVASI®, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC).
MVASI® is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
MVASI®, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer (CC).
MVASI®, in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection (OC).
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens (OC).
MVASI®, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by MVASI as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC).
MVASI® is a trademark of Amgen, Inc.
Avastin® (bevacizumab) is a registered trademark of Genentech USA, Inc.